Private Equity
Ayrmid misses deadline for detailed offer to top private equity bid for bluebird
Ayrmid, Family Turdidae (organism), gene therapy, Failed, Capital, proposal – intent, United States Food and Drug Administration, private equity, deadline
Bluebird Bio’s Fall from Grace: Gene Therapy Pioneer Sells for $29M After $10B Valuation
Bluebird Bio, gene therapy, private equity, Carlyle, SK Capital, financial challenges, acquisition, biotech industry
Bain Capital Acquires Mitsubishi Tanabe Pharma for $3.3 Billion in Strategic Japanese Pharma Investment
Bain Capital, Mitsubishi Tanabe Pharma, acquisition, Japanese pharmaceutical industry, carve-out transaction, private equity, life sciences investment
Grifols Rejects Brookfield’s €6.45 Billion Takeover Bid, Citing Undervaluation
Grifols, Brookfield, takeover offer, undervaluation, private equity
Evotec Shares Soar as Private Equity Firm Triton Considers Takeover Bid
Evotec, Triton Partners, takeover bid, private equity, drug development, pharmaceuticals
Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Private Equity Deal
Avid Bioservices, GHO Capital Partners, Ampersand Capital Partners, biologics CDMO, private equity acquisition, $1.1 billion deal
Symbiotic Capital Launches with $600M, Ties to Arie Belldegrun’s Bellco
Symbiotic Capital, Arie Belldegrun, Bellco, $600M, credit firm, biotech, private equity
Grifols Founding Family and Brookfield Plan to Take Drugmaker Private
Grifols, Brookfield, Private Equity, Takeover Bid, Spanish Drugmaker, Nasdaq, Spanish Stock Exchange
Rovi Receives Acquisition Offers for CDMO Unit Worth €2B to €3B
Rovi, CDMO, Acquisition Offers, Private Equity, Biogen, Deal Making
Sanofi Seeks Private Equity Bids for $20 Billion Consumer Health Division
Sanofi, Consumer Health, Private Equity, Bids, $20 Billion